MedTrace Logo

Management of OAB in Female Patients .

NCT06184334 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2024-04-02

No results posted yet for this study

Summary

The objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (OAB) in a double-blinded prospective randomized placebo-controlled trial.

Conditions

Interventions

DRUG

Solfenacin

pills taken once day

DRUG

Mirabegron

pills taken once day

DRUG

Tadalafil 5mg

pills taken once day

Sponsors & Collaborators

  • Elsayed Abdelhalim Elsayed

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-09-14
Primary Completion
2022-12-01
Completion
2023-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06184334 on ClinicalTrials.gov